/
We are a leading biomedical innovator, addressing significant unmet needs in women s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key internationa…
The business is unprofitable at the operating level (-766.95% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 40.8% YoY with margins expanding 324.8pp.
ROIC dropped from -95.60% to -186.43%, capital efficiency is deteriorating. Negative free cash flow of -$19M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$2M
▲ +40.8% YoY
Net Income (TTM)
-$12M
▲ +1.0% YoY
Op. Margin
-687.93%
▲ +324.8pp YoY
ROIC
-159.78%
▼ -90.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$19M
▲ +4.9% YoY
Op. Cash Flow (TTM)
-$18M
▲ +3.9% YoY
Net Debt
-$658K
Net Cash Position
Cash & Equiv.
$5M
5Y CAGR: +17.2%
Continue Research